Dr. Felix Lansing is the Scientific Co-Founder and Chief Technology Officer at Seamless Therapeutics, a company developing programmable recombinases to treat genetic diseases. With a strong scientific foundation in gene editing, he leads Seamless’ research efforts to establish a pipeline of disease-modifying therapeutic candidates. Dr. Lansing holds a MSc. in Regenerative Biology & Medicine and a PhD in Gene Therapy from TU Dresden on reprogramming and engineering recombinases. His work was recognized by several prestigious awards.